AbbVie Inc. stock price

AbbVie Inc. latest news:


  • 02/20/2018 13:48:29

    3 More Reasons to Buy AbbVie Stock

    These announcements from last week make AbbVie an even better pick for investors.

  • 02/15/2018 11:20:24

    AbbVie Delivers on Promise of Higher Dividend and Stronger Stock Buybacks


  • 02/15/2018 11:00:49

    AbbVie to buy back $10 billion of shares, raises dividend

    Feb 15 (Reuters) - AbbVie Inc on Thursday said its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped benefits from changes to the U.S. tax code.

  • 02/15/2018 11:00:27

    AbbVie stock rises after dividend boosted 35%, new $10 billion buyback program

    Shares of AbbVie Inc. rose 1.0% in midday trade Thursday, after the biopharmaceutical company said it raised its dividend by 35% and set a new $10 billion share repurchase program. The new quarterly dividend of 96 cents a share, up from 71 cents a share, will be payable May 15 to shareholders of record on April 13. Based on current share prices, the new annual dividend rate implies a dividend yield of 3.36%, above the SPDR S&P Pharmaceuticals ETF's payout yield of 0.68% and the S&P 500's implied yield of 1.88%, according to FactSet. The company said its new share buyback program supersedes any existing programs. At current share prices, the program would allow the company to buy back about 87.6 million shares, or 5.5% of the shares outstanding. AbbVie's stock has run up 21.8% over the past three months, while the pharmaceutical ETF has gained 4.6% and the S&P 500 has advanced 5.8%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/26/2018 19:18:41

    AbbVie wins U.S. trial in lawsuit over AndroGel's risks

    (Reuters) - A federal jury in Chicago on Friday found AbbVie Inc not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using the company's testosterone replacement medication AndroGel.

  • 01/26/2018 15:33:28

    Intel and AbbVie jump while Starbucks and Colgate skid

    Intel and AbbVie rally while Starbucks and Colgate-Palmolive fall

  • 01/26/2018 14:04:16

    Wall St. climbs to new highs on strong Intel, AbbVie earnings

    NEW YORK (Reuters) - The latest round of strong earnings reports, including from Intel and AbbVie , along with continued weakness in the dollar lifted each of the major Wall Street indexes to closing records on Friday.

  • 01/26/2018 13:21:59

    US stocks leap as technology and health care companies lead

    Technology and health care companies are climbing following strong results from Intel and AbbVie as stocks round out the week with another big gain

  • 01/26/2018 09:45:11

    S&P, Dow hit records on upbeat Intel, AbbVie earnings

    (Reuters) - U.S. stocks rose to fresh records on Friday, propelled by strong earnings from Intel and drugmaker AbbVie as well as a weaker dollar, putting the three main indexes on track for their best four-week rally since 2016.

  • 01/26/2018 07:00:51

    AbbVie shares rise 3% after Q4 profit, revenue beats, upbeat guidance

    AbbVie Inc. shares rose nearly 3% in pre-market trade after the company reported fourth-quarter profit and revenue beats and released upbeat 2018 guidance. Earnings for the latest quarter declined to $52 million, or 3 cents per share, from $1.39 billion, or 85 cents per share in the year-earlier period. Adjusted earnings-per-share were $1.48, compared with the FactSet consensus of $1.45. Revenue rose to $7.74 billion from $6.80 billion, compared with the FactSet consensus of $7.51 billion. Sales of Humira, Imbruvica, Lupron, Creon, Synagis, Kaletra, Sevoflurane and Duodopa came in above FactSet expectations, while sales of Synthroid and AndroGel missed expectations. AbbVie expects 2018 EPS of $6.45 to $6.55, compared with the FactSet consensus of $5.83, and raised adjusted EPS from between $6.37 and $6.57 to between $7.33 and $7.43, compared with the FactSet consensus of $6.66. The company said its 2017 results reflect provisional amounts related to U.S. corporate tax reform, but that estimates might be adjusted this year. AbbVie also touted plans to increase U.S. investments, including a proposal to invest about $2.5 billion in U.S. capital projects, possible expansion of its U.S. facilities, a one-time charitable donation of about $350 million to U.S. non-profits in 2018, added pension funding of about $750 million and greater compensation for non-executive employees. AbbVie shares have surged 20.9% over the last three months, compared with a 10.9% rise in the S&P 500 and a 12.8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/22/2017 15:51:23

    UPDATE 3-U.S. judge tosses verdict against AbbVie in AndroGel case

    Dec 22 (Reuters) - A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc that was the first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.

  • 12/22/2017 14:02:41

    U.S. judge tosses verdict against AbbVie in AndroGel case

    A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc (ABBV) that was first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.

  • More trends:

    Abercrombie & Fitch CompanyANF | Aberdeen Greater China FundGCH | Aberdeen Japan Equity FundJEQ | Aberdeen Singapore FundSGF | ABM Industries IncorporatedABM | Acadia Realty TrustAKR | Accenture plc.ACN | Acco Brands CorporationACCO | Accuride Corporation NewACW | Ace LimitedACE |